1. Home
  2. IPO
  3. Concord Biotech Ltd Ipo
72610
Off
Concord Biotech IPO

Concord Biotech IPO

  • Status: Closed
  • RHP:
  • ₹ 14,100 / 20 shares

    Minimum Investment

IPO Details

  • Open Date

    04 Aug 2023

  • Close Date

    08 Aug 2023

  • IPO Price Range

    ₹ 705 to ₹ 741

  • IPO Size

    ₹ 1,551 Cr

  • Listing Exchange

    BSE, NSE

  • Listing Date

    18 Aug 2023

With just a few clicks, Invest in IPO's!

+91
Resend OTP

By proceeding, you agree to all T&C*

hero_form
Timeline Subscription Status Objective Financials SWOT FAQ Contacts

IPO Timeline

Concord Biotech IPO Subscription Status

Last Updated: 17 August 2023 11:46 AM by 5Paisa

Concord Biotech Limited IPO is all set to open from 4th August to 8th August 2023. Concord Biotech is an R&D-led biopharma company based out of India. The IPO includes an Offer-for-Sale (OFS) of 20,925,652 equity shares ₹1551 crore. The share allotment date is 11th August, and the IPO will be listed on 18th August on the stock exchanges. The price band is ₹705 to ₹741, and the IPO size is 20 shares.   

Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, and Jefferies India Private Limited are the book-running lead managers for this IPO, while Link Intime India Private Limited is the registrar. 

Objectives of Concord Biotech IPO

Concord Biotech plans to utilize the raised capital from IPO to:

●    Benefit from stock listing on exchanges 
●    To undertake OFS for the selling shareholders
 

Concord Biotech IPO Video:

 

Founded in 1984, Concord Biotech Limited, headquartered in Ahmedabad, is a research and development-driven biopharmaceutical company. It is renowned globally for its expertise in developing and manufacturing Active Pharmaceutical Ingredients (API) using fermentation and semi-synthetic processes, as well as finished formulations. The company has a vast global presence, with over 200 customers in more than 70 countries. It also has a well-established distribution network in key markets such as the USA, Europe, Japan, Latin America, Africa, Asia, and a significant market share in India.

Concord Biotech has 3 manufacturing facilities located in Gujarat, India. Additionally, it has 2 R&D units that have received DSIR (Department of Scientific and Industrial Research) approval, comprising 163 members as of March 31, 2022. The company specializes in producing six fermentation-based immunosuppressant APIs, which include tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus. As of March 31, 2022, the company offered a total of 22 API products. 

Peer Comparison
●    Suven Pharmaceuticals Limited
●    Divi’s Laboratories Limited
●    Shilpa Medicare Limited
●    Laurus Labs Limited
 

For More Information:
Concord Biotech IPO Allotment Status
Webstory on Concord Biotech IPO
Concord Biotech IPO GMP

Profit and Loss

Balance Sheet

Particulars (in Rs. Crores) FY23 FY22 FY21
Revenue 853.16 712.93 616.94
EBITDA 568.42 495.19 317.58
PAT 240.08 174.92 234.88
Particulars (in Rs. Crores) FY23 FY22 FY21
Total Assets 1513.98 1312.79 1182.54
Share Capital - - -
Total Borrowings 223.98 209.57 183.17
Particulars (in Rs. Crores) FY23 FY22 FY21
Net cash generated from / (used in) operating activities 246.00 207.47 166.81
Net cash from / (used in) investing activities -157.94 -111.78 -195.20
Net cash flow from / (used in) financing activities -85.22 -100.16 31.12
Net increase (decrease) in cash and cash equivalents 2.83 -4.47 2.73


Strengths

1.    Concord Biotech held a market share exceeding 20% by volume for fermentation-based Active APIs, including mupirocin in 2022.
2.    The company has a strong presence throughout the complex fermentation value chain.
3.    The company has a diversified global customer base and maintains long-standing relationships with key clients  
4.    It has strong financial performance with rapid growth, consistent profitability, healthy cash flows, and satisfying returns to shareholders. 
5.    The company is dedicated to developing specialized and intricate fermentation-based products having high growth potential.
 

Risks

1.    The company is dependent on a few customers for a major revenue share. 
2.    It is subject to extensive government regulations.
3.    There is a risk of volatile foreign exchange rates.
4.    The working capital needs are on the higher side. 
5.    The company enjoys certain incentive schemes by the government. Any change or discontinuation in availing of such schemes can impact the business operations and profitability. 
6.    Any national or global health emergency or restriction can impact the business. 
7.    Operates in a highly competitive industry.
 

Will You Apply for Concord Biotech IPO?

Yes No Maybe

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
footer_form

FAQs

The minimum lot size of Concord Biotech IPO is 20 shares, and the investment required is ₹14,100.

The price band of Concord Biotech IPO is ₹705 to ₹741.

Concord Biotech IPO opens on 4th August and closes on 8th August 2023.
 

The size of Concord Biotech IPO is ₹1551 crore.

The share allotment date of the Concord Biotech IPO is 11th of August.

The Concord Biotech IPO will be listed on the 18th of August.

Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, and Jefferies India Private Limited are the book-running lead managers for Concord Biotech IPO. 

Concord Biotech plans to utilize the raised capital from IPO to:

1.    Benefit from stock listing on exchanges 
2.    To undertake OFS for the selling shareholders
 

To apply for Concord Biotech IPO, follow the steps given below:
●    Login to your 5paisa account and select the issue in the current IPO section    
●    Enter the number of lots and the price at which you wish to apply for the Concord Biotech Limited  IPO.    
●    Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.    
●    You will receive a mandate notification to block funds in your UPI app.